中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 4
Apr.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(4): 955-958

Research status and challenges in the prognosis of primary biliary cholangitis after liver transplantation

DOI: 10.3969/j.issn.1001-5256.2021.04.050
  • a.

    Department of Hepatology, Changchun 130021, China

  • b.

    Department of Cardiology, The First Hospital of Jilin University, Changchun 130021, China

  • Received Date: 2020-09-22
  • Accepted Date: 2020-10-09
  • Published Date: 2021-04-20
    Abstract
  • Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease with unknown etiology, and patients with poor response to ursodeoxycholic acid and obeticholic acid may eventually progress to liver cirrhosis and even liver failure. Liver transplantation is the only effective treatment method for PBC at present. This article elaborates on liver transplantation, survival time after liver transplantation, complications, recurrence of PBC after liver transplantation, and prospects and challenges of liver transplantation in patients with PBC, so as to provide a reference for clinical outcome and treatment after liver transplantation for PBC.

     

    • FullText(HTML)
  • loading
    • References(47)
  • [1]
    LLEO A, MARZORATI S, ANAYA JM, et al. Primary biliary cholangitis: A comprehensive overview[J]. Hepatol Int, 2017, 11(6): 485-499. DOI: 10.1007/s12072-017-9830-1.
    [2]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis (cholangitis) (2015)[J]. J Clin Hepatol, 2015, 31(12): 1980-1988. DOI: 10.3969/j.issn.1001-5256.2015.12.004.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015, 31(12): 1980-1988. DOI: 10.3969/j.issn.1001-5256.2015.12.004.
    [3]
    XIA ZY, HAN T, MENG HJ. Early immunosuppression combined with ursodeoxycholic acid in the treatment of primary biliary cirrhosis[J]. Chin J Med Offic, 2020, 48(1): 97-98, 101. DOI: 10.16680/j.1671-3826.2020.01.33.

    夏志勇, 韩涛, 孟红军. 早期免疫抑制联合熊去氧胆酸治疗原发性胆汁性肝硬化临床疗效[J]. 临床军医杂志, 2020, 48(1): 97-98, 101. DOI: 10.16680/j.1671-3826.2020.01.33.
    [4]
    NEVENS F, ANDREONE P, MAZZELLA G, et al. A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375(7): 631-643. DOI: 10.1056/NEJMoa1509840.
    [5]
    HIRSCHFIELD GM, MASON A, LUKETIC V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J]. Gastroenterology, 2015, 148(4): 751-761.e8. DOI: 10.1053/j.gastro.2014.12.005.
    [6]
    SHAH RA, KOWDLEY KV. Current and potential treatments for primary biliary cholangitis[J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 306-315. DOI: 10.1016/S2468-1253(19)30343-7.
    [7]
    CHASCSA D, CAREY EJ, LINDOR KD. Old and new treatments for primary biliary cholangitis[J]. Liver Int, 2017, 37(4): 490-499. DOI: 10.1111/liv.13294.
    [8]
    XU L, ZHENG YQ, SHI Z, et al. Influencing factors for the prognosis of primary biliary cholangitis[J]. J Clin Hepatol, 2019, 35(8): 1870-1873. DOI: 10.3969/j.issn.1001-5256.2019.08.050.

    徐黎, 郑玥琪, 时桢, 等. 原发性胆汁性胆管炎预后的影响因素[J]. 临床肝胆病杂志, 2019, 35(8): 1870-1873. DOI: 10.3969/j.issn.1001-5256.2019.08.050.
    [9]
    SCHÖNING W, SCHMEDING M, ULMER F, et al. Liver transplantation for patients with cholestatic liver diseases[J]. Viszeralmedizin, 2015, 31(3): 194-198. DOI: 10.1159/000431017.
    [10]
    SUN CK, CHEN CL, CONCEJERO AM, et al. Liver transplantation for primary biliary cirrhosis in a hepatitis endemic region: A single-center Asian experience[J]. Clin Transplant, 2011, 25(1): 47-53. DOI: 10.1111/j.1399-0012.2010.01288.x.
    [11]
    CARBONE M, NEUBERGER JM. Autoimmune liver disease, autoimmunity and liver transplantation[J]. J Hepatol, 2014, 60(1): 210-223. DOI: 10.1016/j.jhep.2013.09.020.
    [12]
    DICKSON ER, GRAMBSCH PM, FLEMING TR, et al. Prognosis in primary biliary cirrhosis: Model for decision making[J]. Hepatology, 1989, 10(1): 1-7. DOI: 10.1002/hep.1840100102.
    [13]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases[J]. J Hepatol, 2009, 51(2): 237-267. DOI: 10.1016/j.jhep.2009.04.009.
    [14]
    LIBERAL R, ZEN Y, MIELI-VERGANI G, et al. Liver transplantation and autoimmune liver diseases[J]. Liver Transpl, 2013, 19(10): 1065-1077. DOI: 10.1002/lt.23704.
    [15]
    EGAWA H, SAKISAKA S, TERAMUKAI S, et al. Long-term outcomes of living-donor liver transplantation for primary biliary cirrhosis: A Japanese multicenter study[J]. Am J Transplant, 2016, 16(4): 1248-1257. DOI: 10.1111/ajt.13583.
    [16]
    MOTTERSHEAD M, NEUBERGER J. Transplantation in autoimmune liver diseases[J]. World J Gastroenterol, 2008, 14(21): 3388-3395. DOI: 10.3748/wjg.14.3388.
    [17]
    THULUVATH PJ, HANISH S, SAVVA Y. Liver transplantation in cryptogenic cirrhosis: Outcome comparisons between NASH, alcoholic, and AIH cirrhosis[J]. Transplantation, 2018, 102(4): 656-663. DOI: 10.1097/TP.0000000000002030.
    [18]
    BURRA P, GERMANI G, ADAM R, et al. Liver transplantation for HBV-related cirrhosis in Europe: An ELTR study on evolution and outcomes[J]. J Hepatol, 2013, 58(2): 287-296. DOI: 10.1016/j.jhep.2012.10.016.
    [19]
    CHOLANKERIL G, WONG RJ, HU M, et al. Liver transplantation for nonalcoholic steatohepatitis in the US: Temporal trends and outcomes[J]. Dig Dis Sci, 2017, 62(10): 2915-2922. DOI: 10.1007/s10620-017-4684-x.
    [20]
    ADAM R, KARAM V, DELVART V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)[J]. J Hepatol, 2012, 57(3): 675-688. DOI: 10.1016/j.jhep.2012.04.015.
    [21]
    KOSITAMONGKOL P, SANPHASITVONG V, SIRIVATANAUKSORN Y, et al. Outcome of liver transplantation in hepatocellular carcinoma patients at Siriraj Hospital[J]. Transplant Proc, 2017, 49(5): 1114-1117. DOI: 10.1016/j.transproceed.2017.03.047.
    [22]
    SINGH A, FRITZE D, MANSOURI M, et al. Characteristics and outcomes of liver transplantation for primary biliary cholangitis in young patients: Analysis of the United Network for organ sharing database[J]. Transplantation, 2019, 103(6): 1191-1198. DOI: 10.1097/TP.0000000000002501.
    [23]
    GR T M, LEWANDOWSKI Z, PATKOWSKI W, et al. Relevance of male-to-female sex mismatch in liver transplantation for primary biliary cirrhosis[J]. Ann Transplant, 2015, 20: 116-123. DOI: 10.12659/AOT.892394.
    [24]
    HASEGAWA K, SUGAWARA Y, IMAMURA H, et al. Living donor liver transplantation for primary biliary cirrhosis: Petrospective analysis of 50 patients in a single center[J]. Transpl Int, 2005, 18(7): 794-799. DOI: 10.1111/j.1432-2277.2005.00129.x.
    [25]
    COELHO J, LEITE LO, MOLENA A, et al. Biliary complications after liver transplantation[J]. Arq Bras Cir Dig, 2017, 30(2): 127-131. DOI: 10.1590/0102-6720201700020011.
    [26]
    ABAD CL, LAHR BD, RAZONABLE RR. Epidemiology and risk factors for infection after living donor liver transplantation[J]. Liver Transpl, 2017, 23(4): 465-477. DOI: 10.1002/lt.24739.
    [27]
    NEMES B, GÁMÁN G, DOROS A. Biliary complications after liver transplantation[J]. Expert Rev Gastroenterol Hepatol, 2015, 9(4): 447-466. DOI: 10.1586/17474124.2015.967761.
    [28]
    LEVITSKY J, GOLDBERG D, SMITH AR, et al. Acute rejection increases risk of graft failure and death increcent liver transplant recipients[J]. Clin Gastroenterol Hepatol, 2017, 15(4): 584-593.e2. DOI: 10.1016/j.cgh.2016.07.035.
    [29]
    UEMURA T, IKEGAMI T, SANCHEZ EQ, et al. Late acute rejection after liver transplantation impacts patient survival[J]. Clin Transplant, 2008, 22(3): 316-323. DOI: 10.1111/j.1399-0012.2007.00788.x.
    [30]
    MILKIEWICZ P, GUNSON B, SAKSENA S, et al. Increased incidence of chronic rejection in adult patients transplanted for autoimmune hepatitis: Assessment of risk factors[J]. Transplantation, 2000, 70(3): 477-480. DOI: 10.1097/00007890-200008150-00014.
    [31]
    NEUBERGER J, PORTMANN B, MACDOUGALL BR, et al. Recurrence of primary biliary cirrhosis after liver transplantation[J]. N Engl J Med, 1982, 306(1): 1-4. DOI: 10.1056/NEJM198201073060101.
    [32]
    CAMPSEN J, ZIMMERMAN M, TROTTER J, et al. Liver transplantation for primary biliary cirrhosis: Results of aggressive corticosteroid withdrawal[J]. Transplant Proc, 2009, 41(5): 1707-1712. DOI: 10.1016/j.transproceed.2008.10.095.
    [33]
    MANOUSOU P, ARVANITI V, TSOCHATZIS E, et al. Primary biliary cirrhosis after liver transplantation: Influence of immunosuppression and human leukocyte antigen locus disparity[J]. Liver Transpl, 2010, 16(1): 64-73. DOI: 10.1002/lt.21960.
    [34]
    MONTANO-LOZA AJ, WASILENKO S, BINTNER J, et al. Cyclosporine A protects against primary biliary cirrhosis recurrence after liver transplantation[J]. Am J Transplant, 2010, 10(4): 852-858. DOI: 10.1111/j.1600-6143.2009.03006.x.
    [35]
    JACOB DA, HAASE E, KLEIN F, et al. Donor influence on outcome in patients undergoing liver transplant for primary biliary cirrhosis[J]. Exp Clin Transplant, 2010, 8(2): 104-110. http://europepmc.org/abstract/MED/20565366
    [36]
    KANEKO J, SUGAWARA Y, TAMURA S, et al. Long-term outcome of living donor liver transplantation for primary biliary cirrhosis[J]. Transpl Int, 2012, 25(1): 7-12. DOI: 10.1111/j.1432-2277.2011.01336.x.
    [37]
    BOSCH A, DUMORTIER J, MAUCORT-BOULCH D, et al. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence[J]. J Hepatol, 2015, 63(6): 1449-1458. DOI: 10.1016/j.jhep.2015.07.038.
    [38]
    NEUBERGER J. Recurrent primary biliary cirrhosis[J]. Liver Transpl, 2003, 9(6): 539-546. DOI: 10.1053/jlts.2003.50096.
    [39]
    AKAMATSU N, SUGAWARA Y. Primary biliary cirrhosis and liver transplantation[J]. Intractable Rare Dis Res, 2012, 1(2): 66-80. DOI: 10.5582/irdr.2012.v1.2.66.
    [40]
    CARBONE M, NEUBERGER J. Liver transplantation in PBC and PSC: Indications and disease recurrence[J]. Clin Res Hepatol Gastroenterol, 2011, 35(6-7): 446-454. DOI: 10.1016/j.clinre.2011.02.007.
    [41]
    CARBONE M, MELLS GF, ALEXANDER GJ, et al. Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation[J]. Am J Transplant, 2013, 13(4): 1110-1111. DOI: 10.1111/ajt.12132.
    [42]
    SHIBA H, WAKIYAMA S, FUTAGAWA Y, et al. Switching from tacrolimus to cyclosporine A to prevent primary biliary cirrhosis recurrence after living-donor liver transplantation[J]. Int Surg, 2013, 98(2): 156-159. DOI: 10.9738/CC188.
    [43]
    BHANJI RA, MASON AL, GIRGIS S, et al. Liver transplantation for overlap syndromes of autoimmune liver diseases[J]. Liver Int, 2013, 33(2): 210-219. DOI: 10.1111/liv.12027.
    [44]
    GAUTAM M, CHERUVATTATH R, BALAN V. Recurrence of autoimmune liver disease after liver transplantation: A systematic review[J]. Liver Transpl 2006, 12: 1813-1824. DOI: 10.1002/lt.20910.
    [45]
    SILVEIRA MG, TALWALKAR JA, LINDOR KD, et al. Recurrent primary biliary cirrhosis after liver transplantation[J]. Am J Transplant, 2010, 10(4): 720-726. DOI: 10.1111/j.1600-6143.2010.03038.x.
    [46]
    CHARATCHAROENWITTHAYA P, PIMENTEL S, TALWALKAR JA, et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation[J]. Liver Transpl, 2007, 13(9): 1236-1245. DOI: 10.1002/lt.21124.
    [47]
    RACZYNSKA J, HABIOR A, PACZEK L, et al. Primary biliary cirrhosis in the era of liver transplantation[J]. Ann Transplant, 2014, 19: 488-493. DOI: 10.12659/AOT.890753.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (644) PDF downloads(53) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return